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Background: Adenosinedi-phosphate receptor antagonists (ADPRAs)blunt hemostasis for several days after admin-
istration. This effect, aimed at preventing cardiac ischemic complications particularly in patientswith acute coronary
syndromes (ACS), may increase perioperative bleeding in the case of cardiac surgery. Practice Guidelines recom-
mend withholding ADPRAs for at least 5 days prior to surgery, though with a weak base of evidence. The purpose
of this study was to systematically review observational and experimental studies of early or late preoperative dis-
continuation of ADPRAs prior to coronary artery bypass grafting (CABG) for patients with ACS.
Methods:MEDLINE, EMBASE, the Cochrane Library databases up to December 2011; and reference lists.
Observational and experimental studies that compared early ADPRA discontinuation with late discontinuation, or
no discontinuation, in patients with ACS undergoing CABG.35
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EResults: There were 19 studies, including 14,046 participants, 395 deaths and 309 reoperations due to bleeding.ADPRA late discontinuation up to CABG was associated with an increased risk of postoperative mortality (OR1.46, 95% confidence interval (CI) 1.10 to 1.93) and reoperations due to bleeding (OR 2.18; 95% CI 1.47 to 2.62).
Between-study heterogeneity was low.Meta-analysis limited to high quality or prospective studies gave consistent
results. In most instances, the 95% prediction intervals for summary risk estimates confirmed the risk across study
groups.
Conclusions: ADPRA late discontinuation prior to CABG is associated with an increased risk of death and
reoperations due to bleeding in patients with ACS. The confidence in the estimates of risk for late discontinuation
is moderate to high.44© 2012 Published by Elsevier Ireland Ltd.456O
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C1. Introduction
The platelet adenosine di-phosphate receptor antagonists (ADPRAs)
are extensively used in patients with coronary artery disease (CAD) [1].
In stable CAD, they are given in combination with aspirin in order to
prevent stent thrombosis after elective angioplasty. In acute coronary
syndrome (ACS), regardless of stent implantation, they have been
shown to reduce the aggregate risk of cardiovascular death, myocardial
infarction (MI) and stroke by almost 20% by acting on an activated
thrombotic milieu [2–6].68
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me from adenosine di-phosph
a-analysis and meta-regressioTreatment prior to angioplasty is recommended by current guidelines
in order to prevent early ischemic events [1]. However, since two of these
agents (clopidogrel and prasugrel) exert an irreversible antiplatelet effect,
and the third (ticagrelor) is a powerful, though reversible, blocker, an
increased risk of perioperative bleeding exists in the case of urgent coro-
nary artery bypass grafting (CABG). In this setting, preoperative ADPRA
administration has been associated with increased rates of transfusion
and re-operation to stop bleeding. Regardless of the antiplatelet regimen,
reoperation due to bleeding is generally uncommon in patients undergo-
ing elective CABG (about 1.5%) [7]. However this risk is increased in the
case of urgent bypass surgery (4–15% amongACS patients) possibly due
to preoperative antithrombotic treatments [8,9]. Reoperation to stop
bleeding is associated with worse clinical outcomes and a 4.5 fold
higher mortality [10,11]. On this basis, withholding ADPRAs prior to
cardiac surgery might decrease re-exploration rate, chest tube drainageate receptor antagonist discontinuation to coronary bypass surgery in
n, Int J Cardiol (2013), http://dx.doi.org/10.1016/j.ijcard.2012.12.087
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and post-operative mortality. Based upon multiple reviews and cohort
studies, current guidelines recommend discontinuing ADPRAs for at
least 5 days, and preferably 7 days, before CABG in order to reduce
bleeding complications [12–16].
However, whereas this recommendation seems to be safe in elective
CABG patients, the risk versus benefit of ADPRA discontinuation in ACS
patients remains unclear.
Therefore, the aim of this meta-analysis was to determine whether
early compared to late discontinuation of ADPRAs affects the postoper-
ative course of CABG in ACS patients, and to define the optimal timing of
ADPRA discontinuation prior to surgery.
2. Methods
2.1. Eligibility
Thismeta-analysis has been registeredwith PROSPERO—theNHR International Prospec-
tive Register of Systematic Reviews (CRD42011001865) [17]. We followed a priori study el-
igibility criteria for study selection. We included any observational and experimental study
that compared any early discontinuation of ADPRA drugs to later discontinuation treatment
or no discontinuation for patients with ACS referred to CABG surgery. We excluded studies
with fewer than 50% of patientswith ACS, thosewithout a comparison group and those pub-
lished in languages other than English.
Evidence from observational studies was included because it is unlikely that patients
were randomized to receive immediate or postponed surgery after ADPRA administration
to obtain evidence of the mortality-delay association. Furthermore observational studies
may provide important additional information to RCTswith regard to specific populations,
administration modes, and outcomes, especially mortality.
We did not define a priori an optimal time for ADPRA discontinuation but accepted
what the authors claimed as the reference point between early and late discontinuation,
within an interval of maximum seven days.
2.3. Search strategy
Studies were identified by searching electronic databases and scanning reference lists of
articles. This search was applied to Medline, and adapted for EMBASE and the Cochrane
Library [i.e. Cochrane Central Register of Controlled Trials, the Cochrane Database of
Systematic Reviews and Database of Abstracts of Reviews of Effects (DARE)] for studies
published in English between January 2001 and December 2011. The strategy was devel-
oped using the search terms “clopidogrel”, “thienopyridine”, “ticagrelor”, “prasugrel”, ADP
receptor antagonist”, “antiplatelet therapy”, “coronary artery bypass”, “coronary artery
bypass graft”, “graft occlusion”, and “graft patency”. The reference lists of relevant papers,
including other systematic reviews focusing on this topic, and abstracts presented at the
European and American Cardiology Congresses (2006–2012) were also searched.
2.4. Data extraction
Theprimary outcomewaspostoperativemortality (b30 days) and the secondary out-
come was re-operation due to bleeding.
The exposure under consideration was ADPRA administration during 2–7 days
preceding CABG. The control group was defined as any other antiplatelet treatment
during 2–7 days preceding CABG, such as aspirin or no treatment.
We developed a data extraction sheet, pilot-tested it on five randomly-selected studies,
and refined it accordingly. One review author (NM) extracted the following data from stud-
ies included and entered in the data extraction form: patient demographics and baseline
characteristics, the ADPRA loading dose, the number of ADPRA-free days before surgery,
the perioperative use of antifibrinolytic drugs, primary and secondary endpoints. A second
author (JAO) checked the extracted data to ensure quality. Disagreements were solved by
discussion between the two review authors; if no agreement was reached, a third author
(VR) could decide.
For all studies, we recorded the number of treated-patients, the number of non treated-
patients and the number of events in each group in order to estimate the odds ratios (OR)
and corresponding 95% confidence intervals (CI).
Data concerning transfusion requirements, myocardial infarction, chest-tube drainage,
and the duration of hospitalizationwere not included because of the heterogeneity of defini-
tions, indications and measures applied in the different studies.
2.5. Methodological quality
Methodological quality was independently assessed by two review authors (NM and
AS). The Newcastle–Ottawa (NOS) scale for cohort and case-control studies was used
[18,19]. This scale has three groups of items: selection, exposure/outcome and compara-
bility. A study can be awarded a maximum of one star for each numbered item in ‘patient
selection’ (four items) and ‘exposure or outcome’ (for case-control or cohort studies re-
spectively) (three items) and a maximum of two stars in the ‘comparability of study
groups’ (two items), for a total of nine stars. Since we were interested in mortality of op-
erated patients, we expected three items would be scored positively across all studies,
specifically ascertainment of exposure (secure ADPRA administration), demonstrationPlease cite this article as: Morici N, et al, Time from adenosine di-phosph
patients with acute coronary syndrome: Meta-analysis and meta-regressiothat outcome of interest was not present at the start of the study, and assessment of out-
come (record linkage). The same three items were verified for studies reporting only the
secondary endpoint. In fact, in our meta-analysis, the NOS scale could have ranged be-
tween three and nine. For randomized controlled trials (RCTs) we summarized the risk
of bias for mortality within study across the following specific domains: sequence gener-
ation, allocation concealment, and incomplete outcome data [18].We decided a priori that
only observational studies that met eight or nine of the Newcastle–Ottawa Scale criteria
were to be considered of high quality, whereas RCTs were considered of high quality if
they satisfied two or more components. The Newcastle–Ottawa quality scoring assess-
ment is reported in Appendix, Table 1.E
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2.6. Statistical analysis
Wedid an overall quantitative synthesis using all ORs formortality computed from the
frequencies obtained from each study. The results were pooled using the Mantel–Haenszel
random effects model described by DerSimonian and Laird [20] and ordered by study year.
Random effects model was used to synthesize data rather than the fixed effects model be-
cause they incorporate within- and between-study variability. This model was selected a
priori as themeta-analysis was expected to include primarily observational studieswith in-
herently more variability than RCTs. A Mantel–Haenszel estimate was also computed and
compared to the DerSimonian and Laird estimate to investigate any influence of small
study effects on the pooled OR, since the DerSimonian and Laird methods tend to attribute
greater weight to small studies with increasing heterogeneity. The heterogeneity across
studies was assessed by the I-squared statistic and corresponding p-value. We explored
meta-analytic prediction intervals asmeans for providinga clear, appropriate and robust fu-
ture treatment summary reflecting current estimates [21]. Theprediction interval estimates
the possible treatment effect in a future study, and if it includes the null value of one it is
possible that the direction of the treatment effect in a single study may not be the same
as that from the meta-analysis.
Pooled estimates were computed for each stratum of time from ADPRA discontinua-
tion to surgery. Pooled ORs were obtained even for the secondary endpoints throughout
the same approach.We also computed the predictive interval for the approximate predic-
tive distribution of a future trial, based on the extent of heterogeneity, for both outcomes.
Sensitivity analysis was performed to account for differences between the studies. Data
were synthesized for study design (RCT, prospective and retrospective studies), for
study quality (high and low qualities), for time from ADPRA discontinuation to surgery
(b3, b4, b5, b7 days), and percentage of diabetic patients (>30% and b30%).
The extent to which study-level variables explained heterogeneity in predictingmortal-
ity and re-operation due to bleeding was explored by fitting random effect meta-regression
models to account for the time fromADPRAdiscontinuation to surgery (b3,b4, b5,b7 days).
We checked for potential publication and small study effects by the visual inspection of con-
tour enhanced funnel plot [22,23], and the test proposed by Harbord [24].
We used theGrading of RecommendationsAssessment, Development, and Evaluation
(GRADE) guidelines in order to rate the quality of evidence [25]. Factors that affect the
confidence in the estimate of effect include risk for bias (also known as detailed design
and study limitations), imprecision, indirectness (directness in the GRADE approach in-
cludes generalizability and applicability), inconsistency of results (heterogeneity), publi-
cation bias, dose–effect responses, magnitude of effect, and issues of residual plausible
confounding. The confidence in the estimate of effect is categorized into 4 levels, ranging
from very low to high. The completed evidence summaries and GRADE assessments were
discussed by several investigators and reviewed by themethodological and clinical senior
investigators. Evidence summaries were prepared for each research question by using
GRADE Profiler, version 3.6 (McMaster University, Hamilton, Ontario, Canada).
All statistical calculations were performed using ReviewManager (RevMan), version
5.0.24 and STATA version 11.1.3. Results
3.1. Search results
Database searches yielded 602 references, whereas one referencewas
yielded through other sources (“Prasugrel as an anti-thrombotic therapy
in patients with ACS”, presented to the Cardiovascular and Renal Drugs
Advisory Committee, 3 February 2009) (Fig. 1). After screening the ab-
stracts, 62 full-text articles were assessed for eligibility. The final meta-
analysis was based on 19 articles [8,26–42], including 13 observational
studies [8,28–30,32,34–37,39–42], two randomized clinical trials (RCTs)
[27,33], and four post hoc analyses of RCTs [26,31,38,43]. Although the
latter derived fromRCTs, in thismeta-analysis they are classified as obser-
vational since the randomization explored a subject different from the
optimal timing of discontinuation. The other 43 full-text articles were ex-
cluded because they included patientswith stable coronary artery disease
(21 studies), or due to incomplete data availability in order to estimate
the primary and secondary endpoints (19 studies), or due to unknownate receptor antagonist discontinuation to coronary bypass surgery in
n, Int J Cardiol (2013), http://dx.doi.org/10.1016/j.ijcard.2012.12.087
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Database: MEDLINE, EMBASE, COCHRANE
records identified through database
searching
602
Additional records identified
through other sources
1
Total number of duplicates removed: 18
Records screened on basis of
title and abstract: 585
523 excluded because
irrelevant or duplicates
Full-text articles assessed for
eligibility: 62
43 records excluded:
- 21 stable CAD
- 16 study design
- 3 incomplete data to
estimate primary or
secondary endpoint
- 2 timing of clopidogrel
discontinuation unknown
- 1 different
population/intervention
19  studies
included in quantitative
synthesis of systematic review
Fig. 1. Selection for studies exploring the association between post-operative outcome (mortality and reoperation due to bleeding) and optimal time to cardiac surgery in patients
treated with ADPRA therapy.
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timing of ADPRA discontinuation (2 studies) or, finally, different popula-
tion/intervention (1 study).
3.2. Characteristics of studies
We identified 19 studies including 14,046 participants (24.04% fe-
males), with a mean age of 64.5 years. All but two included participants
who were receiving clopidogrel. Another study included clopidogrel
and ticagrelor [26] and the last included clopidogrel and prasugrel
[43]. For the purpose of our meta-analysis, the results of the two study
populations were disaggregated and each analyzed independently.
Table 1 summarizes the characteristics of the studies included in the
meta-analysis. Most studies (12 studies) [8,27–29,31,34–39,43] consid-
ered 5 days prior to surgery as cutoff for early vs late discontinuation,
whereas the remainder used 3 days (4 studies) [32,33,40,41], 4 days
(1 study) [30] and 7 days (1 study) [42]; only the PLATO (Platelet
Inhibition and Patients Outcomes) –CABG trial used 5-day cut-off for
clopidogrel administration and 3 day cut-off for ticagrelor administra-
tion [26]. Seventeen of the 19 studies included information about con-
comitant aspirin treatment [8,26–34,36–38,40–43], the daily doses of
which were 80–150 mg in the RCTs, 75–325 mg in the post-hoc analysis
of RCTs, and 75–325 mg in nine of the observational studies (in the other
26 the dose was not given). Thirteen studies (including the two RCTs)
did not mention the concomitant administration of GPIIb/IIIa inhibitors
[27–29,31–37,39,41,42]. Antifibrinolytic therapies such as tranexamic
acid or aprotinin were not used in 3 studies [40–42], and not mentioned
in 8 [26–29,31,34,36,38]. The administration of ADPRA loading dose was
not specifically mentioned in 10 studies (two RCTs) [27,29,30,32,33,35,
36,38,41,42]; in the remainder between 15.9% and 100% of the patients
received a loading dose.
Three studies [27,34,35] did not mention the percentage of dia-
betic patients; in the others this value varied from 21% to 54%. Five
studies (two RCTs) included only patients undergoing first timePlease cite this article as: Morici N, et al, Time from adenosine di-phosph
patients with acute coronary syndrome: Meta-analysis and meta-regressioCABG [27,28,33,40,41], whereas 12 also included patients undergoing
redo CABG (with percentages varying from 0.3% to 18.5%) [8,29–32,
34,36–39,42], and 2 did not specify [26,35]. A high rate of internal mam-
mary artery graftingwas reported in about 80%of the studies. Two studies
[40,42] (all observational) included only off-pump procedures, and 6
(two RCTs) only on-pump procedures [27,33,35,37,39,41]; the others in-
cluded both, with the rate of on-pump procedures ranging from 1% to
87%. Ten (one RCT) [8,30,32,36,39–42] considered isolated CABG and 7
(oneRCT) [26,28,31,33–35,38] did not specify; the percentage of concom-
itant valve surgery in the remaining papers was between 6.6% and 19.5%.3.3. Mortality
Seventeen studies considered the association between preoperative
ADPRAadministration andpost-operative death, including 3869 patients
with ADPRA early discontinuation (171 deaths) and 8975 patients
with ADPRA late discontinuation (223 deaths). Late or no preoperative
ADPRA discontinuation was associated with an increased rate of post-
operative death (OR 1.46; 95% CI 1.10–1.93) (Fig. 2). The estimated pre-
dictive interval was 0.82–2.59, meaning that an adverse effect of early
surgery after discontinuation might be a plausible finding in a new
study. Between-study heterogeneity was low (I-squared 15.7%). The
Mantel–Haenszel OR was 1.47 (95% CI, 1.16–1.86), suggesting an un-
likely impact of small studies on the random effects estimate towards
more beneficial values. Summary estimates for post-operativemortality
across strata of study design, quality, time from ADPRA discontinuation
to surgery, and percentage of diabetic patients are presented in Fig. 3.
All of the strata were consistent with the overall pooled estimate, al-
though the strata estimates were only significant for prospective (OR
1.69, 95% CI: 1.01–2.81) and high quality (OR 1.45, 95% CI: 1.06–1.99)
studies, and for studies with percentage of diabetic patients >30% (OR
1.43, 95% CI: 1.08–1.88). Timing of discontinuation had a uniform impact,ate receptor antagonist discontinuation to coronary bypass surgery in
n, Int J Cardiol (2013), http://dx.doi.org/10.1016/j.ijcard.2012.12.087
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Table 1t1:1
t1:2 Study characteristics.
t1:3 1st author, year Period of
inclusion
Trial
type
No of subjects Diagnosis Outcome Concomitant
ASA
Concomitant
Antifibrinolytic
REDO-CABG Concomitant
valve surgery
t1:4 Gansera, 2003 2000–2002 Obs 64 Clo ACSe Death; re-op Unknown Unknown Unknown Unknown
t1:5 64 Not Clo
t1:6 Chu, 2004 1999–2001 Obs 41 Clo ACS Death; re-op 70% 76.5% b1% NO
t1:7 271 Not Clo
t1:8 Fox, 2004 1998–2000 Post-hoc 436 Clo ACS Re-op 100% Unknown 4.6% Unknown
t1:9 476 Not Clo
t1:10 Ascione, 2005 2001–2002 Obs 91 Clo ACS Death; re-op 47% Unknown NO Unknown
t1:11 379 Not Clo
t1:12 Akowuah, 2005 2002–2003 RCTg 25 Clo ACS Death; re-op 100% 100% NO NO
t1:13 24 Not Clo
t1:14 Metha, 2006 2003–2004 Obs 739 Clo ACS Death 96% Unknown 13.3% Unknown
t1:15 113 Not Clo
t1:16 Berger, 2008 2007–2007 Obs 298 Clo ACS Death; re-op 91.9% 61% 5.0% NO
t1:17 298 Not Clo
t1:18 Hyung-Jun-Kim, 2008 1999–2003 Obs 332 Clo Mixed Death; re-op 76.7% 10.4% 21.9% NO
t1:19 4462 Not Clo
t1:20 Filsoufi, 2008 1998–2005 Obs 72 Clo Mixed Death; re-op 89% 100% 4.5% NO
t1:21 72 Not Clo
t1:22 Song, 2008 2004–2006 Obs 70 Clo ACS Death; re-op 100% NO NO NO
t1:23 102 Not Clo
t1:24 Tabary, 2008 2003–2006 Obs 154 Clo ACS Re-op 63% NO NO NO
t1:25 136 Not Clo
t1:26 Blasco, 2009 2000–2003 Obs 194 Clo Mixed Death; re-op 100% Unknown 8% 6.4%
t1:27 1483 Not Clo
t1:28 Ebrahimi, 2009 2003–2005 Post-hoc 524 Clo ACS Death; re-op 97.7% Unknown Yes,
Unknown%
Unknown
t1:29 249 Not Clo
t1:30 Firanescu, 2009 2006–2007 RCT 80 Clo Mixed Death; Re-op 100% 100% NO Unknown
t1:31 38 Not Clo
t1:32 Vaccarino, 2009 2003–2006 Obs 123 Clo Mixed Death; re-op 100% NO 4.7% NO
t1:33 981 Not Clo
t1:34 Nesher, 2010 2005–2008 Obs 189 Clo ACS Death; re-op Unknown 100% Clo; %unknown
not Clo
0.3% NO
t1:35 262 Not Clo
t1:36 Mariscalco, 2011 2005–2010 Obs 225 Clo Mixed Death; re-op 100% 100% 1% 19.5%
t1:37 225 Not Clo
t1:38 Held, 2011 2008–2008 Post-hoc Clo:412vs217 ACS Death 100% Unknown Unknown Unknown
t1:39 Tica:304vs328
t1:40 Smith, 2012 2004–2007 Post-hoc Clo:91vs97 ACS Death 100% Unknown 2.9% NO
t1:41 Pra:72vs105
t1:42 aObs=observational studies; Bre-op=reoperation for bleeding; c Clo=clopidgrel group; dMixed=studieswith unknownpercentage of unstable coronary syndromeorwithpercentage
t1:43 >50% but b100%; eACS: acute coronary syndrome; f,h=studies including 2 different comparisons; gRCT=randomized controlled trial.
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although the majority of studies considered five days as cut-off (OR 1.45,
95% CI: 1.01–2.08).
The risk of postoperative mortality in patients who received new
generation ADPRA therapy (prasugrel and ticagrelor) was not increased
in patients with early discontinuation (OR 0.76; 95% CI 0.10–5.57)
(Appendix Fig. 1).300
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3.4. Re-operation due to bleeding
Sixteen studies considered the association between preoperative
ADPRA administration and the rate of re-operation due to bleeding,
including 2883 patients with ADPRA early discontinuation (116 re-
operations) and 8685 patients with ADPRA late discontinuation (193
re-operations). The frequency of re-operation in each study varied be-
tween 1.2% and 12.2% (median 3.2%). Later preoperative ADPRAs were
associated with an increased risk of re-operation due to bleeding (OR
2.18; 95% CI 1.47–3.25) (Fig. 4). The estimated predictive interval was
0.72–6.62, meaning that no effect or an adverse effect of late discontinu-
ationmight be a plausible finding in a new study. Between-study hetero-
geneity was significant (p=0.046) although modest (I-squared 41.7%).
Seven studies were classified as high quality and meta-analysis limited
to prospective studies gave consistent results. All the strata were consis-
tent with the overall pooled estimate, although the strata estimates
were only significant for prospective (OR 2.82; 95% CI 1.52–5.24) and
lowquality (2.49; 95% CI 1.53–4.07) studies, and for percentage of diabet-
ic patients b30% (OR 3.59; 95% CI 1.63–7.89). Discontinuation gavePlease cite this article as: Morici N, et al, Time from adenosine di-phosph
patients with acute coronary syndrome: Meta-analysis and meta-regressiosimilar benefit at all days although the majority of studies considered
five days as cut-off (OR 1.77; 95% CI 1.20–2.62) (Appendix Fig. 2).
3.5. Meta-regression analysis
Time from ADPRA discontinuation to surgery studied with meta-
regression yielded no significant effect on mortality or re-operation due
to bleeding, being the p-values >0.20. Moreover, none of the ORs
changed after adjustment for percentage of diabetic patients (Table 2).
3.6. Small study effects
Visual inspection of the contour-enhanced funnel plot (Fig. 5) indi-
cated that pooled data did not appear to be heavily influenced by pub-
lication bias. This means that slight asymmetry of the plot is possible,
with few studies insisting in the area of significance and the majority
midway in the area of non-significance. The Harbord's test was not sta-
tistically significant (p=0.167).
3.7. Summary findings
The summary findings following the GRADE guidelines are reported
in Table 3. Postoperative mortality is increased by one-half whereas the
risk of re-operation is approximately two times more likely for patients
discontinuing ADPRAs later. This means that, out of 1000 patients
discontinued from ADPRAs early, about 45 would die and about 40
would require re-operation for bleeding. However out of 1000 patientsate receptor antagonist discontinuation to coronary bypass surgery in
n, Int J Cardiol (2013), http://dx.doi.org/10.1016/j.ijcard.2012.12.087
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ADPRAs: Adenosine diphosphate receptor antagonists.
CABG: Coronary artery bypass graft surgery.
Treatment: late-no discontinuation
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Fig. 2. Risk of postoperative mortality in patients who received ADPRA therapy as compared to those who stopped before CABG, stratified according to the time to discontinuation. The
combined OR and 95% CI were calculated using the random-effects models.
5N. Morici et al. / International Journal of Cardiology xxx (2013) xxx–xxxU
Ndiscontinued fromADPRAs later, about 70 (25more patients)would dieand 87 (47 more patients) would need to undergo re-operation to stop
bleeding.
4. Discussion
Our findings, derived from 19 randomized and observational studies
of ADPRAs in patients with an ACS undergoing urgent CABG, indicate
that surgery performed within five days of last drug administration is
associated with increased mortality and reoperation due to bleeding.
Despite the fact that themajority of the information originates from ob-
servational studies, our analysis provides amoderate to high confidence
in the estimates of effect.Moreover, the amount of evidence fromobser-
vational studies increased the precision of the estimateswe found in the
RCTs, with consistent direction and size of the effects. The prediction in-
terval also suggests that further studies are likely to confirm that longerPlease cite this article as: Morici N, et al, Time from adenosine di-phosph
patients with acute coronary syndrome: Meta-analysis and meta-regressiotime of discontinuation is safer than later discontinuation. Unfortunate-
ly, we could not define the best time period for discontinuation, since
the majority of the studies considered five-days as cutoff, and the evi-
dence exploring other cutoff times was sparse and limited.
This conclusion is consistentwith thepharmacologyof currently avail-
able oral ADPRAs and reinforces present guideline recommendations of
discontinuing these agents for at least five days prior to surgery [44,45].
The current recommendation of starting dual antiplatelet therapy with
aspirin and an ADPRA in ACS patients immediately upon admission in
order to prevent early ischemic events is based on the results of the
CURE study [34], but this approach creates a clinical dilemma in those pa-
tientswhowill later showat coronary angiography an indication to CABG.
Fromone side,withdrawal of ADPRAbefore surgerymight expose the pa-
tients to ischemic events in the preoperative period; however, its contin-
uationup to the timeof surgery has been shown to increase postoperative
bleeding. Surgeons have been persuaded to operate on aspirin therapyate receptor antagonist discontinuation to coronary bypass surgery in
n, Int J Cardiol (2013), http://dx.doi.org/10.1016/j.ijcard.2012.12.087
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Fig. 3. Subgroup analysis for postoperative mortality in patients who received ADPRA therapy versus who stopped before CABG. The combined OR and 95% CI were calculated using
the random-effects models.
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Csince the convincing study by Mangano et al. has shown a 60 percentlower mortality and 50 percent reduction in ischemic complicationswithout excess bleeding among patients receiving aspirin within 48 h
after operation [46,47]. However, they are not similarly confident with
ADPRAs due to the increased risk of bleeding complications and lack of
evidence of a protective effect towards early post-operative ischemic
events [48]. Antiplatelet therapy, especially with thienopyridines, may
significantly contribute to cardiopulmonary bypass-induced platelet dys-
function, causing an increase in chest drain blood loss, utilization of blood
products and incidence of re-explorations. Perioperative blood loss de-
manding transfusion has been shown to be associated with an eightfold
increase of death after surgery [49], whereas re-exploration for bleeding
after cardiac surgery is an independent predictor of adverse events such
as sepsis, renal failure, acute respiratory distress syndrome and prolonged
mechanical ventilation [50]. All these consequences can ultimately lead to
death of patients as well as to increased hospital costs [51].
The landmark CURE study, which established the benefit of early
clopidogrel use in addition to aspirin in the secondary prevention of
ischemic events among patients with NSTEACS [34], is of little help for
investigating the impact of this therapy in ACS patients undergoing ur-
gent CABG. As clearly reported in the specific subanalysis of the study,
the median time from index admission to CABG was 25.5 days, 93% of
the patients who proceeded to CABG stopped clopidogrel before
CABG, the median time off the study drug before CABG was 17 days
(interquartile range, 9 to 33) and the median time after CABG was
10 days (interquartile range, 6 to 25) [2,34].
A meta-analysis of 11 observational studies published by Purkayastha
et al. [52] involved 4002 CABG patients: pre-operative continuation of
clopidogrel was independently associated with a significant increase in
major bleeding, reoperation due to bleeding and transfusion require-
ments. Similar results were reported by Pickard et al. [53]. Both meta-
analyses had insufficient power to be conclusive about the risk of death,Please cite this article as: Morici N, et al, Time from adenosine di-phosph
patients with acute coronary syndrome: Meta-analysis and meta-regressioand suffered from heterogeneity between studies. Several other meta-
analyses have beenpublished on this issue over the last years, but they in-
cluded both stable CAD and ACS patients, and showed conflicting results
[10,48]. A recent meta-analysis [54], specifically focused on ACS patients,
showed a trend towards increased mortality (HR 1.44, 95% CI 0.97–2.01,
p=0.07) and reoperation rates among patients undergoing CABG with-
out clopidogrel discontinuation.
Recent data with the newer ADPRA, ticagrelor [26] and prasugrel
[43] in patients with ACS show similar or slightly increased rates of
bleeding and reoperation, however, with significantly reduced mortali-
ty as compared to clopidogrel. Also in the case of these agents, current
guidelines recommend at least five days of discontinuation prior to
surgery.
How complex and confusing is this issue is demonstrated by an
extensive review recently published by Burke et al. [55]. The authors
underline how the ACC/AHA 2007 NSTEACS guidelines endorsed the
use of clopidogrel upstream of coronary angiography in all patients
irrespective of subsequent modality of treatment [56]. The updated
ACC/AHA 2009 guidelines have modified this approach by stating that
clopidogrel may be administrated “before or at the time of PCI”, in pa-
tients with NSTEACS, but they do not give any new evidence to support
this changing recommendation [57]. The same paper, revising data com-
ing from the wide population included in the GRACE [58] and CRUSADE
[59] registries, underscores that clopidogrel is underused in patients
withNSTEACS, and especially in the high risk subgroup, probably because
of concerns about CABG-related bleeding. In the CRUSADE study, in spite
of the national guidelines, 87% of clopidogrel-treated patients underwent
CABG within 5 days after discontinuation of treatment. Both the increas-
ing hospitalization costs and the urgent underlying disease make often
difficult to wait the suggested period. These facts cast doubt on the rec-
ommendation for a fixed safe waiting period following discontinuation
of antiplatelet therapy.ate receptor antagonist discontinuation to coronary bypass surgery in
n, Int J Cardiol (2013), http://dx.doi.org/10.1016/j.ijcard.2012.12.087
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Fig. 4. Risk of re-operation for bleeding inpatientswho receivedADPRA therapy as compared to thosewho stoppedbefore CABG stratified for the time to discontinuation. The combinedORand
95% CI were calculated using the random-effects models.
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Table 2
Random effects meta-regression analysis of postoperative mortality and re-operation for b
stopped before CABG.
No. of studies No. of participants O
Mortality
Cut-off
≤3 4 1034 1b
≤4 1 312 0.
≤5 13 11,234 0.
≤7 1 264 0.
Drug
Ticagrelor/prasugrel 2 809 1b
Other 17 12,035 1.
Re-operation for bleeding
Cut-off
≤3 4 692 1b
≤4 1 312 3.
≤5 10 10,300 0.
≤7 1 264 4.
ADP: adenosine diphosphate.
CABG: coronary artery bypass graft surgery.
a Estimates adjusted for percentage of diabetes.
b Reference category.
Please cite this article as: Morici N, et al, Time from adenosine di-phosph
patients with acute coronary syndrome: Meta-analysis and meta-regressiothe confidence in the results. It adds data on timing of interventions
(such as early vs. late discontinuation), hard outcomes (mortality
and re-operation due to bleeding), subgroups of patients (such asleeding in patients who received ADP receptor antagonist as compared to those who
R (95% CI) p-value OR (95% CI) a rp-value a
1b
38 (0.03–5.78) 0.46 0.33 (0.02–5.95) 0.42
85 (0.29–2.46) 0.75 0.83 (0.30–2.24) 0.68
94 (0.14–6.51) 0.97 0.72 (0.09–5.49) 0.73
1b
22 (0.46–3.24) 0.67 1.18 (0.46–3.02) 0.70
1b
74 (0.45–30.92) 0.20 3.62 (0.36–36.46) 0.23
84 (0.18–3.87) 0.80 0.86 (0.16–4.62) 0.83
71 (0.25–87.79) 0.27 4.09 (0.17–98.59) 0.33
ate receptor antagonist discontinuation to coronary bypass surgery in
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diabetics) and use of newer agents (prasugrel and ticagrelor) that were
not available from previous meta-analyses. Reporting and publication
bias might be limited: the scientific community is alerted and the out-
comes considered relevant.
Our reviewhas limitations that deserve attention for both interpreting
the results and conducting future research. The inclusion of observational
studies increases the risk for bias due to the lack of control for con-
founders and covariates. We could not assess whether different cutoffs
in discontinuation yielded different results. The majority of evidence is
based on a five-day cutoff. The amount of risk might be variable with
different length of drug discontinuation, with a skewed distribution of
the difference between early and late discontinuation. Only few studies
explored discontinuation at the extremes. Our meta-regression which
considered cutoff discontinuation as a continuous outcome has advan-
tages over subgroup analysis: it explores the covariate over an expandedU
N
C
O
R
Table 3
Quality of the evidence according the “Grading of Recommendations Assessment, Developm
ADPRA discontinuation compared to ADPRA continuation for patients with ACS undergoi
Bibliography:
Outcomes No. of participants (studies)
follow up
Quality of the evidence
(GRADE)
R
(
Mortality 12489 ⊕⊕⊕⊕ R
(19 studies) HIGH1 (
30 days
Re-operation for bleeding 11568 ⊕⊕⊕⊝ R
(9 studies) MODERATE1,2 (
30 days Due to inconsistency
*The basis for the assumed risk (e.g. the median control group risk across studies) is provide
assumed risk in the comparison group and the relative effect of the intervention (and its 9
Please cite this article as: Morici N, et al, Time from adenosine di-phosph
patients with acute coronary syndrome: Meta-analysis and meta-regressioE
D
 
range of values. The paucity of studies in some time intervals reduces the
confidence in the absence of differences between alternative cutoff days.
Observational studies can supplement this evidence by contributing data
about special populations (e.g. high risk population, as diabetic patients).
4.1. Clinical implications
Risk stratification for both ischemic and bleeding events is
recommended by current ACS guidelines, especially for patients
presenting without persistent ST-segment elevation [60]. However,
recommended risk scores and algorithmsare of nohelp for estimating the
probability of urgent CABG whose incidence is extremely variable across
centers, and in clinical trials has been shown to range from 10 [31] to 16%
[61,62]. Although the extent of ST-segment changes during acute ische-
mia have been shown to correlate with the presence of three-vesselent, and Evaluation” (GRADE) approach.
ng CABG
elative effect
95% CI)
Anticipated absolute effects
t3:6Time frame is short-term mortality
t3:7Risk with ADPRA discontinuation Risk difference with ADPRA
continuation (95% CI)
R 1.56 Study population
1.2 to 2.03) 45 per 1000 25 more per 1000
(from 9 more to 46 more)
t3:11High
t3:12100 per 1000 56 more per 1000
(from 20 more to 103 more)
R 2.18 Study population
1.47 to 3.25) 40 per 1000 47 more per 1000
(from 19 more to 91 more)
t3:16High
t3:17100 per 1000 118 more per 1000
t3:18(From 47 more to 225 more)
d in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
5% CI).
ate receptor antagonist discontinuation to coronary bypass surgery in
n, Int J Cardiol (2013), http://dx.doi.org/10.1016/j.ijcard.2012.12.087
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disease and left main disease [63], attempts to estimate the probability of
early CABG in ACS have shown only moderate discriminative value [61].
The present data provides solid evidence that performing CABG without
allowing at least five days off ADPRAs in ACS patients is associated with
a significantly increased risk of reoperation to stop bleeding and mortali-
ty. In the lackof comparably solid evidence that administration ofADPRAs
prior to angiography improves outcome in ACS, the present findings
should suggest caution in recommending ADPRA administration prior
to angiography, particularly within the current scenario of very early
angiography across the ACS spectrum [64]. Estimating the probability
of early CABG requires sound clinical judgment, and selective use of
short acting GPIIb/IIIa receptor blockers in patients deemed at risk of ur-
gent surgery may provide adequate antiplatelet protection, as well as
reduction or perioperative ischemic risk, without paying the price of in-
creased perioperative bleeding [65,66].
Appendix A. Supplementary data
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.ijcard.2012.12.087.
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